FTC Forces Watson, Andrx To Sell Drug Lines
Worried about the impact on consumer prices from consolidation in the generic drug industry, the Federal Trade Commission said Tuesday it would approve Watson Pharmaceuticals Inc.'s proposed $1.9 billion acquisition of...To view the full article, register now.
Already a subscriber? Click here to view full article